Jazz Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Record revenue growth continues, with a sharpened focus on rare diseases and robust business development. Key pipeline assets like zanidatamab and Modeyso are advancing, while XYWAV and Epidiolex sustain strong performance. Multiple regulatory and clinical milestones are expected this year.
-
Record 2025 revenue was driven by strong growth in Xywav, Epidiolex, and Modeyso, with continued expansion in oncology and epilepsy. Zanidatamab is advancing rapidly, and strategic investments are focused on rare diseases and pipeline growth. Robust financial resources support ongoing corporate development.
-
Record 2025 revenue and strong growth in epilepsy and oncology set the stage for 2026, with key pipeline advances in zanidatamab and Modeyso. Strategic acquisitions, expanded exclusivity, and a focus on rare diseases drive momentum, supported by robust financial guidance.
-
Record revenues, key product launches, and practice-changing clinical data marked a strong year, with a sharpened focus on rare diseases and robust R&D pipeline. Zanidatamab is poised to become a new standard in HER2-positive GEA, and commercial momentum remains strong despite generic competition.
-
Phase III data show zanidatamab plus chemotherapy, with or without tislelizumab, significantly improves survival outcomes over trastuzumab in first-line HER2-positive GEA, with benefits seen across all PD-L1 subgroups. Regulatory submission and rapid adoption are anticipated.
Fiscal Year 2025
-
Record 2025 revenue of $4.3B was driven by strong growth in rare disease and oncology, with new launches and portfolio expansion. 2026 guidance anticipates continued growth in oncology and epilepsy, offset by sleep franchise headwinds from generics.
-
Record Q3 revenues were driven by strong growth in key brands, with guidance raised and a robust cash position supporting ongoing business development. Oncology and epilepsy remain strategic priorities, with new launches and pipeline advances fueling future growth.
-
Record Q3 revenue was driven by Xywav, Epidiolex, and Modeyso launches, with two new FDA approvals and key litigation settlements. 2025 revenue guidance was narrowed, and the company is preparing for generic Xyrem entry in 2026 while maintaining strong cash flow and a robust pipeline.
-
Early FDA approval for Dodavapene and strong Xywav growth highlight recent progress, while multiple late-stage oncology trials, including the pivotal Horizon 301 for Zanidatamab, are set to deliver key data. Financial discipline and new leadership position the company for future growth.
-
Modeyso received accelerated FDA approval for H3K27M-mutant diffuse midline glioma, showing a 22-28% response rate and favorable safety in clinical studies. The U.S. launch targets academic centers, with strong support services and high awareness among specialists. Patent protection extends to 2037, and international expansion is planned.
-
Q2 2025 revenue grew 2% year-over-year to $1.05 billion, led by strong Xywav and Epidiolex sales, while oncology faced near-term headwinds. Guidance was revised to reflect a modest revenue adjustment but increased confidence in ANI and EPS, with multiple regulatory catalysts ahead.
-
Strong Q1 growth in sleep and neurology, robust cash position, and continued R&D momentum highlight a diversified and resilient business. Key pipeline assets advance with positive ASCO data, while commercial strategies and inventory management buffer against market and regulatory risks.
-
IMforte phase III data show lurbinectedin plus atezolizumab significantly improves survival in first-line maintenance for extensive-stage small cell lung cancer, with manageable safety and broad patient benefit. Regulatory and commercial plans are in place for rapid adoption upon approval.
-
Significant progress was highlighted in commercial, R&D, and corporate development, with strong revenue guidance and durable sleep franchise. Oncology portfolio advances include promising survival data for Zepzelca and zanidatamab, with multiple launches and regulatory milestones expected. Zanidatamab’s broad development strategy and partnership openness were emphasized.
-
Q1 revenue was $898 million, driven by neuroscience growth, while oncology declined but is expected to recover. Pipeline momentum includes key ASCO data, regulatory milestones for ZEPZELCA, zanidatamab, and dordaviprone, and strong financial positioning post-Chimerix acquisition.
-
Q1 2025 saw $898M in revenue, led by Xywav and Epidiolex growth, while oncology faced headwinds. Guidance for 2025 revenue was affirmed at $4.15–$4.4B, with Chimerix acquisition and litigation charges reflected in updated SG&A and R&D outlook.
-
Reported record 2024 revenues and set 2025 growth targets, highlighted new launches and pipeline progress, and discussed the Chimerix acquisition. Key oncology assets, including zanidatamab and dordaviprone, are advancing in pivotal trials with major data and regulatory milestones expected in 2025.
-
Key highlights include the acquisition of Chimerix and its promising glioma therapy, record 2024 revenues, and strong growth in Xywav and Epidiolex. Ziihera and Zepzelca advance in oncology, with pivotal trial readouts and label expansions expected this year.
-
Leadership transition is underway with a focus on sustained growth, capital allocation, and portfolio diversification. Revenue has more than doubled since 2018, driven by new product launches and a robust R&D pipeline, with zanidatamab and Zepzelca as key near-term catalysts.
Fiscal Year 2024
-
Record 2024 revenue of $4.1B (+6% YoY) driven by strong growth in Sleep, Epilepsy, and Oncology. 2025 guidance projects 5% revenue growth, with continued investment in pipeline and capital returns. Ziihera launch, Epidiolex patent settlement, and positive Zepzelca data highlight key milestones.
-
Zanidatamab (Ziihera) secured accelerated FDA approval for second-line HER2-positive BTC, supported by strong efficacy and safety data. The launch targets a $2 billion global opportunity, with ongoing trials in GEA and breast cancer aiming to expand its reach.
-
Record quarterly earnings were driven by strong growth in Xywav, Epidiolex, and Zepzelca. Zanidatamab and Ziihera are advancing in multiple indications, with significant clinical data and expansion opportunities expected in 2024. Robust cash reserves support ongoing M&A and pipeline growth.
-
Q3 2024 saw record revenue and strong growth in neuroscience and oncology, with Xywav and Epidiolex leading sales and Zepzelca showing promise in first-line SCLC. Guidance for total revenue and adjusted net income was affirmed, while Rylaze revenue was temporarily impacted by protocol changes.
-
Record revenues and strong growth in key products and oncology have diversified the business, with zanidatamab positioned as a leading HER2 therapy across multiple cancers. Strategic focus remains on impactful innovation, disciplined capital allocation, and commercial execution, with robust pipeline and patent protection supporting future growth.
-
Record Q2 revenues and strong growth in oncology and sleep franchises were highlighted, with zanidatamab positioned as a best-in-class HER2 therapy and key clinical readouts expected in 2025. Commercial infrastructure and pipeline investments are set to drive long-term growth.
-
Record Q2 revenue above $1B was driven by double-digit growth in neuroscience and oncology, with Xywav, Epidiolex, and Zepzelca as key contributors. 2024 revenue guidance narrowed to $4–$4.1B, and capital allocation remains focused on long-term growth and value creation.
-
Strong Q1 growth and robust cash position support confidence in 2024 guidance. Key milestones include zanidatamab’s FDA review, major data readouts for EPIDIOLEX and suvecaltamide, and continued expansion in oncology and neuroscience.
-
Revenue guidance remains strong with key products driving growth and a robust R&D pipeline led by zanidatamab. Strategic discipline is emphasized for business development, with no plans for value-destructive deals. Market expansion and clinical progress in oncology and sleep disorders are expected to sustain momentum.